NASDAQ : ANIX

Anixa Biosciences, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 3.12 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 108.46M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Details

NameAnixa Biosciences, Inc.
SectorHealthcare
IndustryBiotechnology
Employees4
Founded1982
Ipo Date1987-01-01
CeoAmit Kumar
CountryUnited States
ExchangeNASDAQ
Fiscal YearNovember - October
Reporting CurrencyUSD
IsinUS03528H1095
Cusip03528H109
Cik0000715446
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Dr. Amit Kumar Ph.D.Chief Executive Officer, Chairman and Co-Chair of CBAB
Michael J. Catelani CPA, MBAPresident, Chief Operating Officer, Chief Financial Officer and Corporate Secretary
Dr. Pamela D. Garzone Ph.D.Chief Development Officer and Chair Breast Cancer Clinical Advisory Board

Contact

Address3150 Almaden Expressway, Suite 250, San Jose, California 95118, United States
Phone408 708 9808
Websitehttps://www.anixa.com